
Bio-Techne (TECH) Stock Forecast & Price Target
Bio-Techne (TECH) Analyst Ratings
Bulls say
Bio-Techne is well-positioned to capitalize on a rebound in biotech funding, with a focus on protein sciences and diagnostic and genomics markets. The company also has a strong presence globally, with exposure to key markets such as the US, Europe, and Asia-Pacific. Despite some near-term challenges, including the COVID-19 pandemic and a loss of GMP reagent revenue, Bio-Techne remains focused on self-help opportunities, including the recently announced brand consolidation. The upcoming acquisition of Wilson Wolf could be a significant growth driver for the company, with potential to increase its structural growth and exposure to the cell therapy market. While risks such as potential delays in end market recovery and acquisition risk exist, overall, Bio-Techne's strong product offerings, global operations, and strategic focus make it well-positioned for long-term success in the life sciences industry.
Bears say
Bio-Techne is at risk for a decrease in valuation if the proposed acquisition of Wilson Wolf does not close, the end market recovery for the life science tools industry is delayed or does not occur, and the company experiences share loss due to potential competition and advancements in cell therapy or AI technology. However, the company has a strong track record in making successful acquisitions and is positioning itself for future growth through self-help initiatives. Our downside price target of $38 reflects potential challenges in growth and multiple compression, but we believe the company has strong potential for rebound and profitability with its leverage to the biotech funding rebound and transformative acquisition of Wilson Wolf.
This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.
Bio-Techne (TECH) Analyst Forecast & Price Prediction
Start investing in Bio-Techne (TECH)
Order type
Buy in
Order amount
Est. shares
0 shares